Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

Tue, 24th Oct 2023 17:08

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

London equities were in the red around midday, unlike European peers, as the banking sector weighed on the FTSE 100 following less-than-stellar results from Barclays.

The FTSE 100 index closed up 14.87 points, 0.2%, at 7,389.70. The FTSE 250 ended down 64.89 points, 0.4%, at 16,994.10, and the AIM All-Share closed down 1.96 points, 0.3%, at 678.45.

The Cboe UK 100 ended up 0.2% at 737.16, the Cboe UK 250 closed down 0.5% at 14,738.75, and the Cboe Small Companies ended down 0.2% at 12,692.94.

In European equities, the CAC 40 in Paris ended up 0.6%, while the DAX 40 in Frankfurt ended up 0.5%.

The US private sector saw moderate expansion in October, following largely stagnant output in September and August, according to the latest flash estimate from S&P Global.

The headline S&P Global US purchasing managers' index rose to 51.0 in October, from 50.2 in September. Rising above the 50.0 no-change mark, it signalled a modest up-tick in business activity in the month.

S&P Global said the upturn was supported by expansions in activity for manufacturers and service providers alike. It noted that demand conditions for manufacturers improved for the first time since April, while service providers witnessed a slower drop in new orders.

The flash US manufacturing PMI stood at 50.0 in October, up fractionally from 49.8 in September. The flash US services business activity index stood at 50.9, up from 50.1 last month.

Both flash estimates were better than expected by markets. The sectors had been expected to remain in contraction territory, according to FXStreet-cited consensus.

The dollar gained ground in the wake of the print.

The pound was quoted at USD1.2163 at the London equities close on Tuesday in London, lower compared to USD1.2226 on Monday. The euro stood at USD1.0588, lower against USD1.0639. Against the yen, the dollar was trading at JPY149.90, higher compared to JPY149.79.

Stocks in New York were higher at the London equities close, with the DJIA up 0.6%, the S&P 500 index up 0.6%, and the Nasdaq Composite up 0.7%.

Coca-Cola was up 2.6% in New York at the London close.

The Atlanta, Georgia-based soft drink maker said revenue in the three months to September 29 increased 8.0% on-year to USD11.95 billion from USD11.06 billion. Net income was 9.2% higher at USD3.08 billion from USD2.82 billion.

Coca-Cola now expects organic revenue growth between 10% and 11% in 2023, having previously predicted a rise between 8% and 9%. It now expects comparable currency neutral earnings per share growth of 13% to 14%, lifted from its previous growth range of 9% to 11%.

"Being one of the strongest brands in the world, Coca-Cola's got plenty of staying power, and there's a lot to be said for that in an uncertain environment," said Hargreaves Lansdown analyst Aarin Chiekrie.

Investors also reacted to signs of a cooling UK economy in the latest PMI data.

The S&P Global/CIPS flash UK flash composite PMI rose slightly to 48.6 points in October from 48.5 in September. However, sitting below the 50.0 no change mark, the latest reading suggests the private sector remains in decline.

Looking ahead, S&P said concerns about the outlook for business and consumer spending meant that output growth expectations for the year ahead were the lowest since December 2022.

"Observers will take some comfort from the fact that PMIs do not account for the whole economy, although last week's lacklustre retail sales figures (which are excluded from PMIs) are not especially encouraging," said Handelsbanken analyst Daniel Mahoney.

The unemployment rate for the period for June to August was estimated at 4.2%. This was a 0.2 percentage point increase compared with the period from March to May, the the Office for National Statistics said.

The ONS explained that the figures are an "alternative series of estimates", due to "increased uncertainty" around the Labour Force Survey estimates.

Last month, the ONS said unemployment stood at 4.3% in the three months ended July.

In the FTSE 100, Rio Tinto was the top performer, rising 3.5%, after Barclays raised its rating for the London-based mining company to 'overweight' from 'equal weight'.

AstraZeneca was the second-best performer, rising 3.4% and building on Monday's gains from its Enhertu treatment being approved by the European Commission to treat adult lung cancer patients.

On Tuesday, the Cambridge-based pharmaceutical firm said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine.

The US Food & Drug Administration accepted the drugmaker's supplemental biologics licence application for the needle-free nasal spray. It expects a regulatory decision on the product during the first quarter of 2024. If approved then, FluMist is expected to be available in the US for the 2024/2025 flu season.

If the product is reviewed, it will be the first flu vaccine available to be self-administered, "adding an additional option to be vaccinated against influenza".

Barclays was the second-worst performing FTSE 100 stock, losing 6.5%.

For the quarter that ended September 30, the bank's total income rose 5.2% on-year to GBP6.26 billion from GBP5.95 billion a year prior. However, the figure fell short of the GBP6.29 billion company-compiled consensus.

Barclays reported pretax profit of GBP1.89 billion for the quarter, down 4.3% on-year from GBP1.97 billion. However, it beat the company-compiled market consensus of GBP1.77 billion.

Looking ahead, Barclays backed its annual return on tangible equity forecast of "greater than 10%".

However, it trimmed UK net interest margin guidance. It now expects this to land around "3.05% to 3.10% in 2023".

In a negative read-across, rival banks NatWest and Lloyds Banking were down 1.9% and 1.4%, respectively.

Bunzl lost 4.0% after the distribution firm said revenue in the third-quarter of the year declined by 4.8% at constant exchange rates.

Bunzl put the revenue fall to a "continued decline in Covid-19 related product sales" and a lesser benefit from inflation. It also said there was a "wider post-pandemic related normalisation trends which drove expected volume weakness".

In the FTSE 250, CAB Payments was by far the worst performer, with its shares plunging 72%.

The cross-border payments and foreign exchange firm now expects annual revenue to be "at least" 20% ahead of the GBP109.4 million achieved in 2022. This is about 17% below its previous guidance, however.

It expects the "majority of any revenue impact" will hit its bottom line but will be seeking opportunities to lessen the impact on its bottom line.

Softcat was the second-worst FTSE 250 performer, falling 12%. This was despite reporting "another record year", the IT infrastructure and services provider said.

It reported a pretax profit of GBP141.9 million for the year ended July 31, up 4.2% from GBP136.1 million the year prior. Revenue dropped 8.6% to GBP985.3 million from GBP1.08 billion.

The decline was primarily driven by its Hardware segment, which saw revenue drop 24% year-on-year to GBP610.6 million. Meanwhile, revenue for its Software and Services segments grew 26% and 43%, respectively.

Elsewhere in London, FD Technologies lost 33% after the County Down, Northern Ireland-based group said it swung to a pretax loss of GBP4.5 million in the six months that ended August 31 from a profit of GBP1.1 million a year earlier.

Revenue fell to GBP142.5 million from GBP147.4 million, while it said it expects financial 2024 revenue in the range of GBP285 million to GBP295 million, from GBP296.0 million a year earlier.

Brent oil was lower at USD86.37 a barrel at the London equities close on Tuesday from USD91.05 late Monday. Gold was lower at USD1,963.03 from USD1,977.60.

In Wednesday's UK corporate calendar, a slew of trading statements are released, including by Fresnillo, Ibstock, Lloyds Banking and Reckitt Benckiser.

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.